Fig. 4
From: Mitigation of synaptic and memory impairments via F-actin stabilization in Alzheimer’s disease
Changes in AMPA and NMDA receptor levels in APP/PS1 mice. (a) GluA1 levels in one-month and (b) nine-month-old WT and APP/PS1 mice (n = 8). (c) GluA2 levels in one-month and (d) nine-month-old WT and APP/PS1 mice (n = 8). (e) GluN1 levels in one-month and (f) nine-month-old WT and APP/PS1 mice (n = 8). (g) GluN2A levels in one-month and (h) nine-month-old WT and APP/PS1 mice (n = 8). (i) GluN2B levels in one-month and (j) nine-month-old WT and APP/PS1 mice (n = 8). Statistical comparison between groups was conducted using an unpaired two-tailed t-test. Data are presented as mean ± SEM. Statistical significance: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001